{"id":60605,"date":"2025-01-10T04:03:01","date_gmt":"2025-01-10T03:03:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/"},"modified":"2025-01-10T04:03:01","modified_gmt":"2025-01-10T03:03:01","slug":"meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/","title":{"rendered":"Meiji Seika Pharma Invests in MPM BioImpact\u2019s New Technologies and Virology Strategy"},"content":{"rendered":"
\n

TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter \u201cMeiji\u201d) announced that the company has concluded an investment agreement with MPM BioImpact LLC, a Boston-based biotech investment firm (hereafter \u201cMPM BioImpact\u201d). Meiji has committed to invest USD 20 million in MPM BioImpact\u2019s new technologies and virology strategy as a strategic partner and aims to broaden Meiji\u2019s perspective on early-stage opportunities and enhance its global network.<\/p>\n

<\/a>
<\/a><\/p>\n

\nMPM BioImpact is a world-leading biotechnology investment firm with three decades of experience in creating and investing in innovative companies and aims to deliver transformative therapies to patients. The firm invests in both private and public companies, providing a unique and longitudinal view of drug development across the industry. Its experienced and dedicated team of investment professionals, entrepreneurs, advisors, and leading scientists seeks to translate scientific discoveries into breakthrough medicines and potential cures.<\/p>\n

\nMPM BioImpact invests in companies developing new breakthrough technologies, including next-generation antibodies and biologics, radiopharmaceuticals, nucleic acid therapeutics (e.g., RNA) and cell and gene therapies. These technologies seek to address unmet global medical needs, such as viral and infectious diseases, antimicrobial resistance, and beyond.<\/p>\n

\nThrough this investment and collaboration with MPM BioImpact, Meiji, a frontrunner in infectious disease, aims to acquire new technologies and groundbreaking healthcare solutions in this field. Meiji is committed to advancing innovations, R&D activities, and delivering transformative medicines that meet the unmet needs of patients worldwide.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor further information, please contact:
\n
Sho Takahata
\n
Boston Office (\u2018START Office\u2019), Meiji Pharma USA Inc.
\n
E-mail: mpu.start@meiji.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter \u201cMeiji\u201d) announced that the company has concluded an investment agreement with MPM BioImpact LLC, a Boston-based biotech investment firm (hereafter \u201cMPM BioImpact\u201d). Meiji has committed to invest USD 20 million in MPM BioImpact\u2019s new technologies and virology strategy as a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60605","6":"format-standard","7":"category-industry"},"yoast_head":"\nMeiji Seika Pharma Invests in MPM BioImpact\u2019s New Technologies and Virology Strategy - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Meiji Seika Pharma Invests in MPM BioImpact\u2019s New Technologies and Virology Strategy - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter \u201cMeiji\u201d) announced that the company has concluded an investment agreement with MPM BioImpact LLC, a Boston-based biotech investment firm (hereafter \u201cMPM BioImpact\u201d). Meiji has committed to invest USD 20 million in MPM BioImpact\u2019s new technologies and virology strategy as a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-10T03:03:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250109631783\/en\/774049\/22\/1_Meiji_BrandMark_300.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Meiji Seika Pharma Invests in MPM BioImpact\u2019s New Technologies and Virology Strategy\",\"datePublished\":\"2025-01-10T03:03:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/\"},\"wordCount\":274,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250109631783\\\/en\\\/774049\\\/22\\\/1_Meiji_BrandMark_300.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/\",\"name\":\"Meiji Seika Pharma Invests in MPM BioImpact\u2019s New Technologies and Virology Strategy - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250109631783\\\/en\\\/774049\\\/22\\\/1_Meiji_BrandMark_300.jpg\",\"datePublished\":\"2025-01-10T03:03:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250109631783\\\/en\\\/774049\\\/22\\\/1_Meiji_BrandMark_300.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250109631783\\\/en\\\/774049\\\/22\\\/1_Meiji_BrandMark_300.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Meiji Seika Pharma Invests in MPM BioImpact\u2019s New Technologies and Virology Strategy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Meiji Seika Pharma Invests in MPM BioImpact\u2019s New Technologies and Virology Strategy - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/","og_locale":"en_US","og_type":"article","og_title":"Meiji Seika Pharma Invests in MPM BioImpact\u2019s New Technologies and Virology Strategy - Pharma Trend","og_description":"TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter \u201cMeiji\u201d) announced that the company has concluded an investment agreement with MPM BioImpact LLC, a Boston-based biotech investment firm (hereafter \u201cMPM BioImpact\u201d). Meiji has committed to invest USD 20 million in MPM BioImpact\u2019s new technologies and virology strategy as a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/","og_site_name":"Pharma Trend","article_published_time":"2025-01-10T03:03:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250109631783\/en\/774049\/22\/1_Meiji_BrandMark_300.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Meiji Seika Pharma Invests in MPM BioImpact\u2019s New Technologies and Virology Strategy","datePublished":"2025-01-10T03:03:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/"},"wordCount":274,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250109631783\/en\/774049\/22\/1_Meiji_BrandMark_300.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/","url":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/","name":"Meiji Seika Pharma Invests in MPM BioImpact\u2019s New Technologies and Virology Strategy - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250109631783\/en\/774049\/22\/1_Meiji_BrandMark_300.jpg","datePublished":"2025-01-10T03:03:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250109631783\/en\/774049\/22\/1_Meiji_BrandMark_300.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250109631783\/en\/774049\/22\/1_Meiji_BrandMark_300.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/meiji-seika-pharma-invests-in-mpm-bioimpacts-new-technologies-and-virology-strategy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Meiji Seika Pharma Invests in MPM BioImpact\u2019s New Technologies and Virology Strategy"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60605"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60605\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}